본문 바로가기
  • Home

Comparison of different classes of drugs for Management of Acute Coronary Syndrome (ACS): A brief communication

  • CELLMED
  • Abbr : CellMed
  • 2021, 11(2), pp.7-7
  • DOI : 10.5667/CellMed.2021.0007
  • Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
  • Research Area : Medicine and Pharmacy > General Medicine
  • Received : February 9, 2021
  • Accepted : March 29, 2021
  • Published : May 31, 2021

Jonaid Ahmad Malik 1 Mudasir Maqbool 2 Tawseef Ahmad Hajam 3 Muhammad Abrar Khan 1 Mehrukh Zehravi 4

1National Institute of Pharmaceutical Education and Research
2Department of Pharmaceutical Sciences, University of Kashmir
3University of Kashmir
4Department of Clinical Pharmacy Girls Section, Prince Sattam Bin Abdul Aziz University Alkharj

Accredited

ABSTRACT

Acute coronary syndrome (ACS) is a class of conditions consisting of NSTEMI (non-ST-elevated myocardial infarction), STEMI (ST-elevated myocardial infarction), unstable angina, ranging from myocardial ischaemic states, as well as there is usually a mismatch with respect to both blood supply and blood demand marked by chest pain. Indian patients with ACS have a higher STEMI score than patients of established countries'. Since most of these patients were poor, they were less likely to receive adequate therapy and had a higher death rate of 30 days. In India, ACS patients appear to be young from low socioeconomic backgrounds and have higher ST-elevated MI rates than do patients of established countries'. In India, patients get late medical treatment and inadequate access to proven therapies. Hypertension, hyperlipidemia, diabetes, obesity, cigarette use and a family history of atherosclerotic disease are important risk factors attributed to ACS. Most of the general therapy for ACS focuses on reducing myocardial ischemia and pain suppression. Because of the time dependence of the condition, the onset of signs and arrival at the hospital for the treatment of ACS is very important. This time gap between the onset of symptoms and hospital appearance is larger in India relative to western countries. This paper will concentrate on ACS management and a brief on comparative study of various groups of drugs available with regard to clinical trials and guidelines, respectively.

Citation status

* References for papers published after 2022 are currently being built.